Open AccessEfficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
Author(s) -
Zarir Udwadia,
Pawan Singh,
Hanmant Barkate,
Saiprasad Patil,
Shabbir Rangwala,
Amol Pendse,
Jatin Kadam,
Wen Wu,
Cynthia Caracta,
Monika Tandon
Publication year - 2020
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2020.11.142
Subject(s) - favipiravir , medicine , clinical endpoint , randomized controlled trial , adverse effect , clinical trial , asymptomatic , gastroenterology , covid-19 , disease , infectious disease (medical specialty)
To assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 (COVID-19).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom